Study of a personalized vaccine plus chemo for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced (stage IV) squamous non-small cell lung cancer.
- You must have at least one tumor that can be measured on scans.
- You must provide a tissue sample taken after your cancer spread, from a spot that was not treated with radiation.
- You must not have had any prior chemotherapy or immunotherapy for advanced lung cancer.
- You must be in good enough health to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab (Keytruda) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps the immune system fight the cancer better.
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a personalized approach to combining immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that does not have specific genetic changes (driver mutations). The goal is to see if tailoring treatment based on your immune system can improve outcomes.
Hear when a new Squamous Non-small-cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.